biotricity is a medical technology company committed to improving healthcare by developing solutions that aid chronic disease prevention and management. biotricity’s premier product is bioflux, an ecg monitoring system that will be prescribed by physicians to diagnose and remotely monitor cardiac patients. biotricity is expanding medical-grade monitoring into the consumer market via its biolife solution, which empowers users to self-manage chronic conditions. biolife helps users make lifestyle changes by combining medically relevant ecg data with social media interactivity and a lifestyle log. biotricity’s r&d continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. the company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.
Company profile
Ticker
BTCY
Exchange
Website
CEO
Waqaas Al-Siddiq
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
METASOLUTIONS, INC.
SEC CIK
BTCY stock data
Latest filings (excl ownership)
RW
Registration withdrawal request
25 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Apr 24
424B3
Prospectus supplement
22 Apr 24
D
$1.00 mm in equity / options / securities to be acquired, sold $1.00 mm, 1 investor
9 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
3 Apr 24
8-K
Entry into a Material Definitive Agreement
26 Mar 24
S-1
IPO registration
27 Feb 24
10-Q
2024 Q3
Quarterly report
20 Feb 24
NT 10-Q
Notice of late quarterly filing
14 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Feb 24
Transcripts
BTCY
Earnings call transcript
2024 Q2
14 Nov 23
BTCY
Earnings call transcript
2024 Q1
15 Aug 23
BTCY
Earnings call transcript
2023 Q3
14 Feb 23
BTCY
Earnings call transcript
2023 Q2
15 Nov 22
BTCY
Earnings call transcript
2023 Q1
16 Aug 22
BTCY
Earnings call transcript
2022 Q4
14 Jul 22
BTCY
Earnings call transcript
2022 Q3
16 Feb 22
BTCY
Earnings call transcript
2022 Q2
9 Nov 21
BTCY
Earnings call transcript
2022 Q2
4 Nov 21
BTCY
Earnings call transcript
2022 Q1
18 Aug 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.20 mm | 1.20 mm | 1.20 mm | 1.20 mm | 1.20 mm | 1.20 mm |
Cash burn (monthly) | (no burn) | 108.17 k | 1.23 mm | 1.36 mm | 796.68 k | 773.32 k |
Cash used (since last report) | n/a | 746.09 k | 8.49 mm | 9.36 mm | 5.49 mm | 5.33 mm |
Cash remaining | n/a | 453.64 k | -7.29 mm | -8.16 mm | -4.30 mm | -4.13 mm |
Runway (months of cash) | n/a | 4.2 | -5.9 | -6.0 | -5.4 | -5.3 |
Institutional ownership, Q2 2023
30.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 22 |
Opened positions | 4 |
Closed positions | 9 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 1.63 bn |
Total shares | 2.85 mm |
Total puts | 500.00 |
Total calls | 59.40 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 1.48 mm | $945.58 mm |
Geode Capital Management | 384.20 k | $240.86 mm |
Strengthening Families & Communities | 289.58 k | $185.00 k |
AE Wealth Management | 250.10 k | $159.44 mm |
STT State Street | 135.30 k | $86.25 mm |
BLK Blackrock | 80.24 k | $51.15 mm |
NTRS Northern Trust | 72.00 k | $45.90 mm |
Signature Wealth Management Partners | 37.80 k | $24.10 mm |
PNC PNC Financial Services | 22.72 k | $14.47 mm |
Tower Research Capital | 18.36 k | $11.71 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 23 | Al-Siddiq Waqaas | Option (right to purchase) Common Stock | Grant | Acquire A | No | No | 0.81 | 1,000,000 | 810.00 k | 4,899,984 |
12 Mar 23 | Al-Siddiq Waqaas | Option (right to purchase) Common Stock | Grant | Acquire A | No | No | 1.75 | 350,000 | 612.50 k | 3,899,984 |
12 Mar 23 | Al-Siddiq Waqaas | Option (right to purchase) Common Stock | Grant | Acquire A | No | No | 1.25 | 350,000 | 437.50 k | 3,549,984 |
12 Mar 23 | Rosa David A | Option Common Stock | Grant | Acquire A | No | No | 1.94 | 75,930 | 147.30 k | 474,683 |
News
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
18 Mar 24
Biotricity Unveils That Improved Margins Resulted From Latest Advancements To Its Proprietary Cardiac AI Cloud Platform And Announces Plans For Continued Expansion Of Its Cardiac AI Cloud
12 Mar 24
Biotricity Q3 2024 Adj EPS $(0.12) Beats $(0.44) Estimate, Sales $2.97M Miss $3.00M Estimate
20 Feb 24
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
20 Feb 24
Press releases
Biotricity's Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest from Existing and New Customers
26 Apr 24
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics
18 Apr 24
Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital Network
16 Apr 24
Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities
2 Apr 24
Biotricity Accelerates Market Access by Partnering with Third Major Group Purchasing Organization, Expanding Market Reach to 90% of U.S. Hospitals
28 Mar 24